시장보고서

상품코드

1877391

세계의 항암제 시장 : 투여 경로별, 약제 클래스별, 적응증별, 유통 채널별, 제형별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 규모, 점유율 및 예측(2025-2032년)

Anticancer Drug Market, By Route of Administration, By Drug Class, By Indication, By Distribution Channels, By Dosage Form, By End-Users, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 11월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 398 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항암제 시장 규모는 2024년에 1,666억 6,956만 달러로 평가되었고, 2025년부터 2032년에 걸쳐 CAGR 9.5%를 나타낼 전망입니다.

항암제(항종양제라고도 함)는 악성 또는 암성 세포의 증식과 확산을 막는 약입니다. 본 시장은 주로 세계적인 암 이환율의 상승과 종양학 연구에 대한 투자 증가에 의해 견인되고 있어, 이것에 의해 표적 요법이나 맞춤형 의료의 개발이 진행될 전망입니다. 그러나 항암 치료의 고비용과 엄격한 규제 승인 프로세스가 저·중소득국에서의 접근을 제한하고 있습니다. 그러나 유전자 프로파일 링을 사용하여보다 효과적이고 독성이 낮은 치료 옵션을 제공하는 면역 요법과 정밀 종양학의 진전에는 큰 기회가 있습니다. 생물학적 제형과 병용 요법의 지속적인 혁신이 향후 수년간 시장 성장을 이끌 것으로 예측됩니다.

항암제 시장 - 주요 고려 사항

암 이환율 증가로 시장 성장 촉진

세계적인 암 발생률의 상승은 항암제 시장 성장의 주요 성장 촉진요인 중 하나입니다. 고령화, 생활양식의 변화, 환경오염, 유전적 소인 등이 함께 세계 암 증례가 증가하고 있습니다. 환자 수가 늘어남에 따라 표적 요법, 면역 요법, 맞춤형 의료 등 효과적이고 선진적인 치료법에 대한 수요도 높아지고 있습니다. 이 급증은 제약기업에 대한 연구개발투자의 확대와 환자의 치료성과를 개선하는 신규치료제의 개발을 촉구하고 있습니다. 예를 들어 세계보건기구(WHO)는 신규 암 증례 수가 2018년 1,810만 건에서 2040년까지 2,940만 건으로 증가할 것으로 예상하고 있으며, 혁신적인 항암제의 필요성이 매우 높아 예측 기간 중 시장 성장이 지속됨을 보여줍니다.

항암제 시장 : 세분화 분석

세계의 항암제 시장은 투여 경로, 약물 클래스, 적응증, 유통 경로, 투여 형태, 최종 사용자, 지역에 따라 분류됩니다.

제형별로는 고형제(정제, 캡슐), 주사제(프리필드 시린지, 기타), 액제 등으로 분류됩니다. 이 중 주사제 부문은 유효성 향상과 서방형 제어를 위해 비경구 투여를 필요로 하는 생물학적 제제나 표적 요법의 사용 확대를 배경으로 주요 수익원이 되고 있습니다. 종양학 분야에서는 의료 감독하에 투여하면 정확한 복용량 조정, 신속한 전신 흡수 및 치료 효과 향상이 가능하므로 주사제가 널리 사용되고 있습니다. 게다가, 바이오시밀러와 제네릭 주사제의 가용성이 높아짐에 따라 액세스가 확대되고 시장 성장이 촉진되고 있습니다. 예를 들어, 2020년 9월에는 마이란사가 아스트라제네카사의 패스로덱스(여성의 특정 진행성 유방암 치료제)의 제네릭 의약품인 풀베스트란트 주사액(250mg/5mL)의 미국 발매를 발표했으며, 이 분야에서 지속적인 혁신과 시장 활동을 보여주었습니다.

약물 클래스별로 표적요법은 악성세포를 선택적으로 공격하면서 정상조직에 대한 손상을 최소화하는 능력으로 치료효과 향상과 독성 저감을 실현하기 때문에 항암제 시장에서 중요한 부문입니다. 이 정밀의료 기반 접근법은 질병 메커니즘에 직접 초점을 맞추고 오프 타겟 효과를 최소화하기 때문에 기존의 화학 요법보다 높은 채용률을 나타냅니다. FDA 승인의 단일클론항체, 키나아제 억제제, 면역조절제의 포트폴리오 확대는 암 연구 개발에 있어서 현저한 진전을 나타내고 있습니다. 또한 유전체 검사와 동반진단의 조합으로 치료 정밀도가 향상되어 보다 개별화되고 효과적인 암 치료가 가능해졌습니다. 신규 표적 요법의 승인 증가와 강력한 개발 파이프라인이 결합되어 본 부문 시장 잠재력을 높이고 있습니다. 예를 들어, 2023년 6월에는 미국 FDA가 BRAF V600E 돌연변이를 가진 소아 및 성인 환자에 대한 더블라페닙과 트라메티닙의 병용 요법을 승인했습니다. 이것은 표적 치료 분야의 성장을 견인하는 지속적인 혁신과 임상적 진보를 부각시키는 사례입니다.

항암제 시장 - 지역별 분석

항암제 시장은 의료 인프라, 암 이환율, 선진 치료에 대한 접근 격차로 인해 현저한 지역적 차이를 보이고 있습니다. 아시아태평양은 여전히 시장의 주요 성장 지역이며 세계 점유율의 약 20%를 차지하고 있습니다. 암 발생률의 상승, 의료비 지출 증가, 현대적 종양 치료에 대한 접근 확대가 이 지역의 성장에 기여하고 있습니다. 급속한 도시화, 생활양식의 변화, 고령화가 진행되는 인구구조가 질병유병률의 상승요인이 되고 있습니다. 중국, 인도, 일본 등의 국가들은 암 치료에 대한 수요 증가에 대응하기 위해 종양학 조사, 임상시험, 헬스케어 인프라에 많은 투자를 하고 있습니다. 게다가 환자 의식 증가, 정부의 지원책, 상환 제도의 개선에 의해 표적 치료제, 면역요법, 병용 치료 등의 신규 치료법의 도입이 촉진되고 있습니다.

중국의 항암제 시장 - 국가별 인사이트

중국은 그 방대한 인구, 증가하는 암 이환율, 확대하는 헬스케어 인프라에 의해 아시아태평양의 항암제 시장에서 주요한 견인역이 되고 있습니다. 세계보건기구(WHO)의 데이터에 따르면 중국에서는 2025년에 약 430만건의 신규 암 증례가 발생할 것으로 예측되고 있으며, 폐암, 유방암, 대장암이 가장 흔합니다. 정부는 종양학 조사, 임상시험, 병원 네트워크에 많은 투자를 하고 있습니다. 의식이 높아지고, 표적치료나 면역요법 등의 혁신적 치료에 대한 접근 확대, 그리고 지원적인 상환 정책이 선진적인 항암제의 도입을 가속화하고 있으며, 중국은 지역 내에서 지배적이고 빠르게 성장하는 시장으로서의 지위를 확립하고 있습니다.

항암제 시장 : 경쟁 구도

Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, Johnson & Johnson 등이 항암제 시장의 주요 기업입니다. 이러한 기업들은 표적 요법, 면역종양학, 정밀의료의 진보로 경쟁을 격화시키고 있습니다. 체크포인트 억제제, CAR-T 세포 요법, 항체 약물 복합체(ADC)의 사용 증가는 치료 패러다임을 변화시키고 R&D 투자를 촉진합니다. 각 회사가 종양 파이프라인의 강화와 세계 전개를 도모하는 가운데, 전략적 제휴, 합병, 인수가 자주 행해지고 있습니다. 또한 AI를 활용한 창약 플랫폼과 바이오마커를 기반으로 한 환자 선택의 조합이 혁신을 가속화하고 있습니다. 세계적으로 증가하는 암 부담에 대응하기 위해 경쟁 구도는 급속한 기술 진화, 임상시험의 확대, 그리고 개별화, 비용 효율적인 암 치료에 초점을 맞추는 것으로 특징지어지고 있습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카(MEA)
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제14장 주요 벤더 분석 : 항암제 업계

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 프로파일
- Novartis
- Pfizer
- Merck &Co.(MSD)
- Bristol Myers Squibb(BMS)
- AstraZeneca
- Roche/Genentech
- Johnson &Johnson/Janssen
- Sanofi
- Eli Lilly &Co.
- Takeda
- Amgen
- BeiGene
- Regeneron
- Bluebird Bio
- Seagen
- Moderna
- Genmab
- Incyte
- Exelixis
- Hutchmed/Chi-Med
- 기타

15장 AnalystView의 전방위 분석

KTH

Anticancer Drug Market size was valued at US$ 166,669.56 Million in 2024, expanding at a CAGR of 9.5% from 2025 to 2032.

Anticancer drugs, also known as antineoplastic drugs, are medications that prevent malignant or cancerous cells from growing and spreading. The market is primarily driven by rising global cancer prevalence and increased investments in oncology research, which will result in the development of targeted therapies and personalized medicine. However, the high cost of anticancer treatments and stringent regulatory approval processes limit access in low- and middle-income countries. Nevertheless, significant opportunities exist for the advancement of immunotherapies and precision oncology, which use genetic profiling to provide more effective and less toxic treatment options. Continuous innovation in biologics and combination therapies is expected to drive market growth in the coming years.

Anticancer Drug Market- Market Dynamics

Increasing Prevalence of Cancer to Augment Market Growth

The rising global cancer incidence is one of the primary drivers of the anticancer drug market's growth. Aging populations, changing lifestyles, environmental pollution, and genetic predispositions all contribute to an increase in cancer cases around the world. As the number of patients grows, so does the demand for effective and advanced treatment options such as targeted therapies, immunotherapies, and personalized medicines. This surge is encouraging pharmaceutical companies to increase their R&D investments and develop novel therapeutics to improve patient outcomes. For instance, the World Health Organization (WHO) predicts that the number of new cancer cases will rise from 18.1 million in 2018 to 29.4 million by 2040, highlighting the critical need for innovative anticancer drugs and supporting continued market growth during the forecast period.

Anticancer Drug Market- Segmentation Analysis:

The Global Anticancer Drug Market is segmented on the basis of Route of Administration, Drug Class, Indication, Distribution Channels, Dosage Form, End-Users, and Region.

In terms of Dosage Form, the Anticancer Drug Market is divided into Solid (Tablets, Capsules), Injectable (Prefilled Syringes, Others), Liquid, and Others. Among these, the injectable segment is a significant revenue generator, driven by the growing use of biologics and targeted therapies that require parenteral administration for improved efficacy and controlled release. In oncology, injectables are widely used because they allow for precise dosing, rapid systemic absorption, and improved treatment outcomes when administered under medical supervision. Moreover, the increasing availability of biosimilars and generic injectable formulations is broadening access and driving market expansion. For example, in September 2020, Mylan N.V. announced the U.S. launch of Fulvestrant Injection (250 mg/5 mL), a generic version of AstraZeneca's Faslodex used to treat certain types of advanced breast cancer in women, demonstrating ongoing innovation and market activity in this segment.

Based on drug class, targeted therapy is an important segment of the anticancer drug market due to its ability to selectively attack malignant cells while minimizing damage to healthy tissues, thereby improving treatment efficacy and lowering toxicity. This precision-based approach focuses directly on disease mechanisms while minimizing off-target effects, resulting in higher adoption than conventional chemotherapy. The growing portfolio of FDA-approved monoclonal antibodies, kinase inhibitors, and immune-modulating agents demonstrates significant progress in cancer research and development. Furthermore, the combination of genomic testing and companion diagnostics has increased treatment accuracy, allowing for more personalized and effective cancer care. The growing number of regulatory approvals for novel targeted therapies, combined with a strong pipeline of investigational drugs, is boosting this segment's market potential. For instance, in June 2023, the US FDA approved the combination of dabrafenib and trametinib for pediatric and adult patients with BRAF V600E-mutated cancers, highlighting the ongoing innovation and clinical progress that is driving growth in the targeted therapy segment.

Anticancer Drug Market- Geographical Insights

The Anticancer Drug Market exhibits notable regional diversity, shaped by differences in healthcare infrastructure, cancer prevalence, and access to advanced therapies. Asia-Pacific remains a key growth region for the market, accounting for roughly 20% of the global share. The rising incidence of cancer, increased healthcare expenditure, and expanded access to modern oncology treatments all contribute to growth in this region. Rapid urbanization, lifestyle changes, and an ageing population all contribute to the rise in disease prevalence. Countries such as China, India, and Japan are investing heavily in oncology research, clinical trials, and healthcare infrastructure to meet the rising demand for cancer care. Furthermore, increased patient awareness, supportive government initiatives, and improved reimbursement frameworks are easing the adoption of novel therapies such as targeted drugs, immunotherapies, and combination treatments.

China Anticancer Drug Market- Country Insights

China's large population, rising cancer prevalence, and expanding healthcare infrastructure make it a key driver of the Asia-Pacific anticancer drugs market. According to World Health Organization data, China is expected to see approximately 4.3 million new cancer cases in 2025, with lung, breast, and colorectal cancers being the most common. The government is making substantial investments in oncology research, clinical trials, and hospital networks. Increased awareness, access to innovative therapies such as targeted treatments and immunotherapies, and supportive reimbursement policies are hastening the adoption of advanced anti-cancer drugs, establishing China as a dominant and rapidly growing market in the region.

Anticancer Drug Market- Competitive Landscape:

Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, and Johnson & Johnson are among the anticancer drug market key players. These companies are fueling competition with advances in targeted therapies, immuno-oncology, and precision medicine. The increasing use of checkpoint inhibitors, CAR-T cell therapies, and antibody-drug conjugates (ADCs) is changing treatment paradigms and driving R&D investments. Strategic collaborations, mergers, and acquisitions are common as companies seek to strengthen their oncology pipelines and expand globally. In addition, the combination of AI-powered drug discovery platforms and biomarker-based patient selection is hastening innovation. To address the increasing global cancer burden, the competitive landscape is characterized by rapid technological evolution, clinical trial expansion, and a focus on personalized, cost-effective cancer therapies.

Recent Developments:

In October 2025, AstraZeneca and Daiichi Sankyo announced that Datroway, a precision drug, improved survival rates in patients with advanced breast cancer in a late-stage trial. This development paves the way for more widespread approvals and possible market expansion.

In June 2025, Bristol Myers Squibb signed a $11 billion strategic collaboration agreement with BioNTech. The collaboration entails the co-development and commercialization of BioNTech's investigational bispecific antibody, BNT327, which targets a variety of solid tumor types. BioNTech received an initial payment of $1.5 billion, with non-contingent anniversary payments through 2028 and potential milestone payments of up to $7.6 billion. This collaboration represents a significant investment in the advancement of novel immuno-oncology therapies in the global anticancer drug market, intending to accelerate the development of this bispecific antibody in multiple indications.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTICANCER DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Novartis
Pfizer
Merck & Co. (MSD)
Bristol Myers Squibb (BMS)
AstraZeneca
Roche/Genentech
Johnson & Johnson/Janssen
Sanofi
Eli Lilly & Co.
Takeda
Amgen
BeiGene
Regeneron
Bluebird Bio
Seagen
Moderna
Genmab
Incyte
Exelixis
Hutchmed / Chi-Med
Others

GLOBAL ANTICANCER DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Intravenous (IV)
Subcutaneous
Oral
Topical / Localized

GLOBAL ANTICANCER DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Chemotherapy
Immunotherapy (Checkpoint inhibitors, CAR-T, TCR therapies)
Monoclonal Antibodies / Biologics
Hormone Therapy
Targeted Therapy
Others (Oncolytic viruses, combination therapies, adjuncts)

GLOBAL ANTICANCER DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Breast Cancer
Lung Cancer
Prostate Cancer
Gastrointestinal Cancer
Blood Cancer
Gynaecologic Cancer
Others

GLOBAL ANTICANCER DRUG MARKET, BY DISTRIBUTION CHANNELS- MARKET ANALYSIS, 2019 - 2032

Online Pharmacy
Hospital Pharmacy
Retail Pharmacy

GLOBAL ANTICANCER DRUG MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

Solid (Tablets, Capsule)
Injectable (Prefilled Syringes, Others)
Liquid
Others

GLOBAL ANTICANCER DRUG MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032

Specialty Clinics
Hospitals
Homecare
Others

GLOBAL ANTICANCER DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Anticancer Drug Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Anticancer Drug Market Snippet by Route of Administration
- 2.1.2. Anticancer Drug Market Snippet by Drug Class
- 2.1.3. Anticancer Drug Market Snippet by Indication
- 2.1.4. Anticancer Drug Market Snippet by Distribution Channels
- 2.1.5. Anticancer Drug Market Snippet by Dosage Form
- 2.1.6. Anticancer Drug Market Snippet by End-Users
- 2.1.7. Anticancer Drug Market Snippet by Country
- 2.1.8. Anticancer Drug Market Snippet by Region
2.2. Competitive Insights

3. Anticancer Drug Key Market Trends

3.1. Anticancer Drug Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Anticancer Drug Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Anticancer Drug Market Opportunities
3.4. Anticancer Drug Market Future Trends

4. Anticancer Drug Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Anticancer Drug Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Anticancer Drug Market Landscape

6.1. Anticancer Drug Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Anticancer Drug Market - By Route of Administration

7.1. Overview
- 7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
- 7.1.2. Intravenous (IV)
- 7.1.3. Subcutaneous
- 7.1.4. Oral
- 7.1.5. Topical / Localized

8. Anticancer Drug Market - By Drug Class

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
- 8.1.2. Chemotherapy
- 8.1.3. Immunotherapy (Checkpoint inhibitors, CAR-T, TCR therapies)
- 8.1.4. Monoclonal Antibodies / Biologics
- 8.1.5. Hormone Therapy
- 8.1.6. Targeted Therapy
- 8.1.7. Others (Oncolytic viruses, combination therapies, adjuncts)

9. Anticancer Drug Market - By Indication

9.1. Overview
- 9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 9.1.2. Breast Cancer
- 9.1.3. Lung Cancer
- 9.1.4. Prostate Cancer
- 9.1.5. Gastrointestinal Cancer
- 9.1.6. Blood Cancer
- 9.1.7. Gynaecologic Cancer
- 9.1.8. Others

10. Anticancer Drug Market - By Distribution Channels

10.1. Overview
- 10.1.1. Segment Share Analysis, By Distribution Channels, 2024 & 2032 (%)
- 10.1.2. Online Pharmacy
- 10.1.3. Hospital Pharmacy
- 10.1.4. Retail Pharmacy

11. Anticancer Drug Market - By Dosage Form

11.1. Overview
- 11.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
- 11.1.2. Solid (Tablets, Capsule)
- 11.1.3. Injectable (Prefilled Syringes, Others)
- 11.1.4. Liquid
- 11.1.5. Others

12. Anticancer Drug Market - By End-Users

12.1. Overview
- 12.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
- 12.1.2. Specialty Clinics
- 12.1.3. Hospitals
- 12.1.4. Homecare
- 12.1.5. Others

13. Anticancer Drug Market- By Geography

13.1. Introduction
- 13.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
13.2. North America
- 13.2.1. Overview
- 13.2.2. Anticancer Drug Key Manufacturers in North America
- 13.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.2.7. North America Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.2.8. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.2.9. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.2.10. U.S.
  - 13.2.10.1. Overview
  - 13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.2.10.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.2.10.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.2.10.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.2.10.6. U.S. Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.2.10.7. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.2.10.8. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.2.11. Canada
  - 13.2.11.1. Overview
  - 13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.2.11.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.2.11.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.2.11.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.2.11.6. Canada Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.2.11.7. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.2.11.8. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3. Europe
- 13.3.1. Overview
- 13.3.2. Anticancer Drug Key Manufacturers in Europe
- 13.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.7. Europe Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.8. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.9. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.10. Germany
  - 13.3.10.1. Overview
  - 13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.10.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.3.10.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.3.10.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.3.10.6. Germany Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.3.10.7. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.3.10.8. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.11. UK
  - 13.3.11.1. Overview
  - 13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.11.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.3.11.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.3.11.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.3.11.6. UK Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.3.11.7. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.3.11.8. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.12. France
  - 13.3.12.1. Overview
  - 13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.12.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.3.12.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.3.12.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.3.12.6. France Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.3.12.7. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.3.12.8. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.13. Italy
  - 13.3.13.1. Overview
  - 13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.13.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.3.13.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.3.13.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.3.13.6. Italy Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.3.13.7. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.3.13.8. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.14. Spain
  - 13.3.14.1. Overview
  - 13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.14.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.3.14.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.3.14.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.3.14.6. Spain Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.3.14.7. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.3.14.8. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.15. The Netherlands
  - 13.3.15.1. Overview
  - 13.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.15.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.3.15.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.3.15.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.3.15.6. The Netherlands Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.3.15.7. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.3.15.8. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.16. Sweden
  - 13.3.16.1. Overview
  - 13.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.16.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.3.16.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.3.16.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.3.16.6. Sweden Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.3.16.7. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.3.16.8. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.17. Russia
  - 13.3.17.1. Overview
  - 13.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.17.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.3.17.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.3.17.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.3.17.6. Russia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.3.17.7. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.3.17.8. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.18. Poland
  - 13.3.18.1. Overview
  - 13.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.18.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.3.18.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.3.18.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.3.18.6. Poland Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.3.18.7. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.3.18.8. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.19. Rest of Europe
  - 13.3.19.1. Overview
  - 13.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.19.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.3.19.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.3.19.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.3.19.6. Rest of the Europe Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.3.19.7. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.3.19.8. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.4. Asia Pacific (APAC)
- 13.4.1. Overview
- 13.4.2. Anticancer Drug Key Manufacturers in Asia Pacific
- 13.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.4.7. APAC Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.4.8. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.4.9. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.10. China
  - 13.4.10.1. Overview
  - 13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.10.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.4.10.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.4.10.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.4.10.6. China Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.4.10.7. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.4.10.8. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.11. India
  - 13.4.11.1. Overview
  - 13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.11.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.4.11.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.4.11.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.4.11.6. India Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.4.11.7. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.4.11.8. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.12. Japan
  - 13.4.12.1. Overview
  - 13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.12.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.4.12.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.4.12.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.4.12.6. Japan Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.4.12.7. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.4.12.8. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.13. South Korea
  - 13.4.13.1. Overview
  - 13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.13.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.4.13.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.4.13.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.4.13.6. South Korea Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.4.13.7. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.4.13.8. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.14. Australia
  - 13.4.14.1. Overview
  - 13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.14.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.4.14.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.4.14.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.4.14.6. Australia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.4.14.7. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.4.14.8. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.15. Indonesia
  - 13.4.15.1. Overview
  - 13.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.15.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.4.15.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.4.15.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.4.15.6. Indonesia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.4.15.7. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.4.15.8. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.16. Thailand
  - 13.4.16.1. Overview
  - 13.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.16.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.4.16.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.4.16.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.4.16.6. Thailand Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.4.16.7. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.4.16.8. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.17. Philippines
  - 13.4.17.1. Overview
  - 13.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.17.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.4.17.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.4.17.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.4.17.6. Philippines Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.4.17.7. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.4.17.8. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.18. Rest of APAC
  - 13.4.18.1. Overview
  - 13.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.18.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.4.18.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.4.18.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.4.18.6. Rest of APAC Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.4.18.7. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.4.18.8. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.5. Latin America (LATAM)
- 13.5.1. Overview
- 13.5.2. Anticancer Drug Key Manufacturers in Latin America
- 13.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.5.7. LATAM Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.5.8. LATAM Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.5.9. LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.5.10. Brazil
  - 13.5.10.1. Overview
  - 13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.10.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.5.10.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.5.10.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.5.10.6. Brazil Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.5.10.7. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.5.10.8. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.5.11. Mexico
  - 13.5.11.1. Overview
  - 13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.11.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.5.11.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.5.11.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.5.11.6. Mexico Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.5.11.7. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.5.11.8. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.5.12. Argentina
  - 13.5.12.1. Overview
  - 13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.12.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.5.12.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.5.12.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.5.12.6. Argentina Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.5.12.7. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.5.12.8. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.5.13. Colombia
  - 13.5.13.1. Overview
  - 13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.13.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.5.13.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.5.13.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.5.13.6. Colombia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.5.13.7. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.5.13.8. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.5.14. Rest of LATAM
  - 13.5.14.1. Overview
  - 13.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.14.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.5.14.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.5.14.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.5.14.6. Rest of LATAM Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.5.14.7. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.5.14.8. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.6. Middle East and Africa
- 13.6.1. Overview
- 13.6.2. Anticancer Drug Key Manufacturers in Middle East and Africa
- 13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.6.8. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.6.9. Middle East and Africa Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.10. Saudi Arabia
  - 13.6.10.1. Overview
  - 13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.10.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.6.10.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.6.10.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.6.10.6. Saudi Arabia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.6.10.7. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.6.10.8. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.11. United Arab Emirates
  - 13.6.11.1. Overview
  - 13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.11.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.6.11.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.6.11.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.6.11.6. United Arab Emirates Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.6.11.7. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.6.11.8. United Arab Emirates Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.12. Israel
  - 13.6.12.1. Overview
  - 13.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.12.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.6.12.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.6.12.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.6.12.6. Israel Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.6.12.7. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.6.12.8. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.13. Turkey
  - 13.6.13.1. Overview
  - 13.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.13.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.6.13.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.6.13.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.6.13.6. Turkey Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.6.13.7. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.6.13.8. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.14. Algeria
  - 13.6.14.1. Overview
  - 13.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.14.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.6.14.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.6.14.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.6.14.6. Algeria Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.6.14.7. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.6.14.8. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.15. Egypt
  - 13.6.15.1. Overview
  - 13.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.15.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.6.15.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.6.15.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.6.15.6. Egypt Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.6.15.7. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.6.15.8. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.16. Rest of MEA
  - 13.6.16.1. Overview
  - 13.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.16.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 13.6.16.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 13.6.16.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 13.6.16.6. Rest of MEA Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
  - 13.6.16.7. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 13.6.16.8. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)

14. Key Vendor Analysis- Anticancer Drug Industry

14.1. Competitive Benchmarking
- 14.1.1. Competitive Dashboard
- 14.1.2. Competitive Positioning
14.2. Company Profiles
- 14.2.1. Novartis
- 14.2.2. Pfizer
- 14.2.3. Merck & Co. (MSD)
- 14.2.4. Bristol Myers Squibb (BMS)
- 14.2.5. AstraZeneca
- 14.2.6. Roche/Genentech
- 14.2.7. Johnson & Johnson/Janssen
- 14.2.8. Sanofi
- 14.2.9. Eli Lilly & Co.
- 14.2.10. Takeda
- 14.2.11. Amgen
- 14.2.12. BeiGene
- 14.2.13. Regeneron
- 14.2.14. Bluebird Bio
- 14.2.15. Seagen
- 14.2.16. Moderna
- 14.2.17. Genmab
- 14.2.18. Incyte
- 14.2.19. Exelixis
- 14.2.20. Hutchmed / Chi-Med
- 14.2.21. Others

15. 360 Degree Analyst View

16. Appendix

16.1. Research Methodology
16.2. References
16.3. Abbreviations
16.4. Disclaimer
16.5. Contact Us